Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2019
Reporting Period: Event effective November 25, 2019
Context: The Company, an emerging growth company incorporated in New Jersey, filed this report to disclose amendments to its Certificate of Incorporation regarding a reduction in authorized stock and a reverse stock split.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The following metrics are not provided in the source text:
- Revenue: Not provided
- Profit/Loss: Not provided
- Cash Flow: Not provided
- Margins: Not provided
- Debt and Liquidity: Not provided
Material Changes
The filing details two material corporate actions effective November 25, 2019:
- Reduction of Authorized Stock: The Company reduced its authorized common stock at a ratio of one-for-eight.
- Reverse Stock Split: The Company effected a reverse stock split of authorized and outstanding common stock at a ratio of one-for-twenty-four.
Impact on Share Count:
- Outstanding shares reduced to: 521,676
- Authorized shares reduced to: 2,604,167
Shareholder Impact: The actions affected all stockholders uniformly without altering percentage equity interests. Fractional shares were not issued; instead, holdings were rounded up to the nearest whole number.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations or financial projections.
Risks and Contingencies: No specific risks or contingencies are disclosed in this document beyond the standard implications of a reverse stock split (e.g., rounding of fractional shares).
Investor Verification Checklist
- Verify the post-split share count of 521,676 outstanding shares in subsequent filings.
- Confirm the new authorized share limit of 2,604,167.
- Check for any subsequent filings regarding the trading symbol adjustment or delisting risks associated with the reverse split.
- Review the Company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.